Blood biologic markers of stroke: Improved management, reduced cost?

Current Atherosclerosis Reports

Volumn 8, Issue 4, 2006, Pages 267-275

  Baird, Alison E ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BIOLOGICAL MARKER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; PHOSPHOLIPASE A2; PROTEOME; ROSUVASTATIN;

ATHEROSCLEROSIS; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; EARLY DIAGNOSIS; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GENETIC CODE; GENETIC RISK; HUMAN; HYPERTENSION; LABORATORY TEST; MARKER GENE; PATHOPHYSIOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; PRIMARY PREVENTION; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL MARKERS; CAUSALITY; CEREBROVASCULAR ACCIDENT; COST CONTROL; GENE EXPRESSION PROFILING; HUMANS; OXIDATIVE STRESS; RECURRENCE; STROKE;

EID: 33745888060     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-006-0003-2     Document Type: Review

References (50)

1. Hill MD: Diagnostic biomarkers for stroke: a stroke neurologist's perspective. Clin Chem 2005, 51:2001-2002.
2. Goldstein LB, Simel DL: Is this patient having a stroke? JAMA 2005, 293:2391-2402.
3. Norris JW, Hachinski VC: Misdiagnosis of stroke. Lancet 1982, 1:328-331
4. Hand PJ, Kwan J, Lindley RI, et al.: Distinguishing between stroke and mimic at the bedside. The Brain Attack Study. Stroke 2006, 37:769-775.
5. Kidwell CS, Chalela JA, Saver JL, et al.: Comparison of MRI and CT for detection of acute intracerebral hemorrhage. JAMA 2004, 292:1823-1830.
6. Baird AE, Dambrosia J, Janket S, et al.: A three-item scale for the early prediction of stroke recovery. Lancet 2001, 357: 2095-2099.
7. Mayer SA, Brun NC, Begtrup K, et al.: Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005, 352:777-785.
8. Lees KR, Zivin JA, Ashwood T, et al.: NXY-059 for acute ischemic stroke. N Engl J Med 2006, 354:588-600.
9. Hsieh KM, Blumenthal HT: Serum lactic dehydrogenase levels in various disease states. Proc Soc Exp Biol Med 1956, 91: 626-630.
10. Biomarkers Definitions Working Group: Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95.
11. Griffiths HR, Moller L, Bartosz G, et al.: Biomarkers. Mol Aspects Med 2002, 23:101-208.
12. Echt DS, Liebson PR, Mitchell LB, et al.: Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991, 324:781-788.
13. Mitka M: Biomarkers for coronary heart disease: predictive value or background noise? JAMA 2004, 292:2824-2845.
14. Brotman DJ, Walker E, Lauer MS, O'Brien RG: In search of fewer independent risk factors. Arch Intern Med 2005, 165:138-145.
15. Greenland P, O'Malley PG: When is a new prediction marker useful? A consideration of lipoprotein-associated phospholipase A2 and C-reactive protein for stroke risk. Arch Intern Med 2005, 165:2454-2456.
16. Margolis KL, Manson JE, Greenland P, et al.: Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women's Health Initiative Observational Study. Arch Intern Med 2005, 165:500-508.
17. Elkind MS, Sciacca RR, Boden-Albala B, et al.: Relative elevation in baseline leukocyte count predicts first cerebral infarction. Neurology 2005, 64:2121-2125.
18. Dubo H, Park DC, Pennington RJ, et al.: Serum-creatine-kinase in cases of stroke, head injury, and meningitis. Lancet 1967, 2:743-748.
19. Kaste M, Somer H, Kontinnen A: Brain-type creatine kinase iso-enzyme. Arch Neurol 1977, 34:142-144.
20. Bell RD, Rosenberg RN, Ting R, et al.: Creatine kinase BB isoenzyme levels by radio-immuno-assay in patients with neurological disease. Ann Neurol 1978, 3:52-59.
21. Norris JW, Hachinski VC, Myers MG, et al.: Serum cardiac enzymes in stroke. Stroke 1979, 10:548-553.
22. Persson L, Hardemark HG, Gustafsson J, et al.: S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system. Stroke 1987, 18:911-918.
23. Fassbender K, Schmidt R, Schreiner A, et al.: Leakage of brain-originated proteins in peripheral blood: temporal profile and diagnostic value in early ischemic stroke. J Neurol Sci 1997, 148:101-105.
24. Sharp FR, Lu A, Tang Y, Millhorn DE: Multiple molecular penumbras after focal cerebral ischemia. J Cereb Blood Flow Metab 2000, 20:1011-1032.
25. Onteniente B, Rasika S, Benchoua A, Guegan C: Molecular pathways in cerebral ischemia: cues to novel therapeutic strategies. Mol Neurobiol 2003, 27:33-72.
26. Weinstein PR, Hong S, Sharp FR: Molecular identification of the ischemic penumbra. Stroke 2004, 35(Suppl 1):2666-2670.
27. Castillo J, Rodriguez I: Biochemical changes and inflammatory response as markers for brain ischaemia: molecular markers of diagnostic utility and prognosis in human clinical practice. Cerebrovasc Dis 2004, 17(Suppl):17-18.
28. Cherubini A, Ruggiero C, Polidori MC, Mecocci P: Potential markers of oxidative stress in stroke. Free Radic Biol Med 2005, 39:841-852.
29. Vila N, Castillo J, Davalos A, Chamorro A: Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke 2000, 31:2325-2329.
30. Castellanos M, Leira R, Serena J, et al.: Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 2003, 34:40-46.
31. Ransohoff DF: Developing molecular markers for cancer. Science 2003, 299:1679-1680.
32. Calvano SE, Xiao W, Richards DR, et al.: A network-based analysis of systemic inflammation in humans. Nature 2005, 437:1032-1037.
33. Sebastiani P, Ramoni MF, Nolan V, et al.: Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia. Nat Genet 2005, 37:435-440.
34. Moore DF, Li H, Jeffries N, et al.: Using peripheral blood mononuclear cells to determine a gene expression profile of acute ischemic stroke: a pilot investigation. Circulation 2005, 111:212-221.
35. Tang Y, Xu H, Du X, et al.: Gene expression in blood changes rapidly in neutrophils and monocytes after ischemic stroke in humans: a microarray study. J Cereb Blood Flow Metab 2006, In press.
36. Lynch JR, Blessing R, White WD, et al.: Novel diagnostic test for acute stroke. Stroke 2004, 35:57-63.
37. Reynolds MA, Kirchick HJ, Dahlen JR, et al.: Early biomarkers of stroke. Clin Chem 2003, 49:1733-1739.
38. Allard L, Burkhard PR, Lescuyer P, et al.: PARK7 and nucleoside diphosphate kinase A as plasma markers for the early diagnosis of stroke. Clin Chem 2005, 51:2043-2051.
39. Allard L, Lescuyer P, Burgess J, et al.: ApoC-I and ApoC-III as potential plasmatic markers to distinguish between ischemic and hemorrhagic stroke. Proteomics 2004, 4:2242-2251.
40. Simak J, Gelderman M, Yu H, et al.: Elevated circulating endothelial microparticles in acute stroke patients: a correlation with brain lesion volume and clinical outcome. Blood 2004, 104:954.
41. Nadar SK, Lip GY, Lee KW, Blann AD: Circulating endothelial cells in acute ischaemic stroke. Thromb Haemost 2005, 94:707-712.
42. Nadareishvili ZG, Li H, Wright V, et al.: Elevated proinflammatory CD4+CD28- lymphocytes and stroke recurrence and death. Neurology 2004, 63:1446-1451.
43. Garlichs CD, Kozina S, Fateh-Moghadam S, et al.: Upregulation of CD40-CD40 ligand (CD154) in patients with acute cerebral ischemia. Stroke 2003, 34:1412-1418.
44. Paczkowska E, Larysz B, Rzeuski R, et al.: Human hematopoietic stem/ progenitor-enriched CD34(+) cells are mobilized into peripheral blood during stress related to ischemic stroke or acute myocardial infarction. Eur J Haematol 2005, 75:461-467.
45. Elkind M, Coates A, Tai W, Sacco RL: Lipoprotein-associated phospholipase A2 and C-reactive protein as predictors of stroke recurrence and death: The Northern Manhattan Stroke Study. Stroke 2006, 37:625-626.
46. Libby P: Inflammation in atherosclerosis. Nature 2002, 420:868-874.
47. Ballantyne CM, Hoogeveen RC, Bang H, et al.: Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med 2005, 165:2479-2484.
48. Di Napoli M, Schwaninger M, Cappelli R, et al.: Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. Stroke 2005, 36:1316-1329.
49. Smith SC Jr, Anderson JL, Cannon RO 3rd, et al.: CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the clinical practice discussion group. Circulation 2004, 110:e550-e553.
50. Ridker PM; JUPITER Study Group: Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 2003, 108:2292-2297.